New Enterprise Associates
New Enterprise Associates is a venture capital firm founded in 1977 and based in Menlo Park, California, with offices in the United States, India and China. It makes investments across technology and healthcare startups at multiple stages, from seed to growth, including software, cloud, data, internet services, fintech, AI, e-commerce, and enterprise technology, as well as healthcare information technology, life sciences, medical devices, and biopharma. It also considers energy technology and infrastructure opportunities, such as solar, batteries and smart grids. The firm pursues a global approach, with activity in the United States, Asia and other regions, and supports companies through rounds of financing ranging from small to sizable investments as they scale. NEA focuses on building portfolios in software, IT services, consumer technology, and healthcare technology, backing ambitious entrepreneurs across sectors and geographies.
Top Sectors
Top Regions
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Alabama
Slope.io
Series A in 2021
Slope.io, Inc. is a company that specializes in clinical trial logistics, catering to sponsors, contract research organizations (CROs), and research sites throughout the United States. Founded in 2016 and based in Mobile, Alabama, Slope.io offers a platform that streamlines the operational complexities associated with clinical trials. Its Slope.io Coordination service converts logistics requirements into organized schedules and workflows, while the Slope.io Kitting service provides customizable supply kits tailored to specific sites, patients, or study time points. The company emphasizes real-time coordination and complete traceability of devices, drugs, and kits from suppliers to research sites and patients.
Nektar Therapeutics
Post in 2011
Nektar Therapeutics is a biopharmaceutical company focused on developing novel drugs for cancer and autoimmune diseases. Its pipeline includes Bempegaldesleukin (NKTR-214), a CD122-preferential interleukin-2 pathway agonist designed to activate cancer-killing T cells and NK cells, currently in Phase I/II trials. The company also develops other immunotherapies such as NKTR-358 for autoimmune diseases and NKTR-262 for oncology, both in Phase I trials.
Encompass Health
Venture Round in 1995
Encompass Health Corporation is a leading provider of facility-based and home-based post-acute healthcare services in the United States. The company operates primarily through two segments: Inpatient Rehabilitation and Home Health and Hospice. The Inpatient Rehabilitation segment offers specialized rehabilitative treatment for patients recovering from a variety of conditions, including strokes, neurological disorders, cardiac and pulmonary issues, and complex orthopedic conditions. In contrast, the Home Health and Hospice segment delivers a range of Medicare-certified services, including skilled nursing, therapy, and hospice care, primarily in the Southeast and Texas. As of November 2020, Encompass Health operated 137 hospitals, 242 home health locations, and 83 hospice sites across 39 states and Puerto Rico. Founded in 1983 and headquartered in Birmingham, Alabama, the company was previously known as HealthSouth Corporation before rebranding in January 2018.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.